Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ZLY28 is a novel, first-in-class compound with specific intestinal restriction and oral activity, serving as a dual modulator of FXR and FABP1. Additionally, it is a pioneering anti-NASH agent, utilized in the study of nonalcoholic steatohepatitis (NASH) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | 35 days | $ 353.00 | |
5 mg | 35 days | $ 1,490.00 |
Description | ZLY28 is a novel, first-in-class compound with specific intestinal restriction and oral activity, serving as a dual modulator of FXR and FABP1. Additionally, it is a pioneering anti-NASH agent, utilized in the study of nonalcoholic steatohepatitis (NASH) [1]. |
In vitro | ZLY28 exhibits suitable hepatic microsomal stability and high target selectivity toward FXR (EC50 = 143 nM) and FABP1 (IC50 = 2.7 μM)[1]. |
In vivo | ZLY28 (oral; 20 mg/kg) significantly ameliorates fatty liver in a NASH mouse model by modulating various pathogenic mechanisms, including lipid metabolism, inflammation, oxidative stress, and fibrosis [1]. |
Molecular Weight | 520.4 |
Formula | C29H23Cl2NO4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ZLY28 Metabolism FXR inhibitor inhibit